TherapeuticsMD (TXMD) Invested Capital (2010 - 2022)

TherapeuticsMD (TXMD) has reported Invested Capital for 9 consecutive years, with $47.1 million the latest figure, recorded in Q3 2022.

• For the quarter ending Q3 2022, Invested Capital fell 63.61% year-over-year to $47.1 million; the trailing twelve-month figure through Sep 2022 stood at $47.1 million (down 63.61% YoY), and the FY2021 full-year result was $94.6 million, down 16.75% from the prior year.
• Invested Capital declined to $47.1 million in Q3 2022 per TXMD's latest filing, from $64.7 million in the prior quarter.
• Across five years, Invested Capital topped out at $207.5 million in Q3 2018 and bottomed at $47.1 million in Q3 2022.
• Historically, Invested Capital has averaged $141.0 million across 5 years, with a median of $143.0 million in 2020.
• The sharpest annual moves came in 2020 and 2022: Invested Capital jumped 47.71% in 2020, then plunged 65.3% in 2022.
• Over 5 years, Invested Capital stood at $170.9 million in 2018, then gained by 19.27% to $203.8 million in 2019, then tumbled by 44.22% to $113.7 million in 2020, then retreated by 16.75% to $94.6 million in 2021, then tumbled by 50.26% to $47.1 million in 2022.
• According to Business Quant data, Invested Capital over the past three periods registered $47.1 million, $64.7 million, and $62.3 million for Q3 2022, Q2 2022, and Q1 2022 respectively.